Paper Details

  1. Home
  2. Paper Details

Ustekinumab Treatment and Improvement of Physical Function and Health-Related Quality of Life in Patients With Psoriatic Arthritis.

Author: , GottliebAlice B, HanChenglong, KavanaughArthur, LiShu, McInnesIain B, MendelsohnAlan, PuigLluis, RahmanProton, RitchlinChristopher, SongMichael, WangYuhua

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Ustekinumab significantly improved patient-reported outcomes in patients with active psoriatic arthritis (PsA) regardless of prior methotrexate (MTX) or anti-tumor necrosis factor (TNF) use. Ustekinumab was associated with clinically meaningful improvements in HAQ DI, DLQI, and SF-36 scores.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To examine the effects of ustekinumab on patient-reported outcomes (PROs) in PSUMMIT 1 and PSUMMIT 2 patients with active psoriatic arthritis (PsA) who were methotrexate (MTX) naive, MTX experienced, or anti-tumor necrosis factor (TNF) experienced. METHODS: Patients in the phase 3, PSUMM...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5132036/

データ提供：米国国立医学図書館（NLM）

Ustekinumab Treatment for Psoriatic Arthritis

This study examines the effects of ustekinumab, a medication used to treat psoriasis and psoriatic arthritis, on patient-reported outcomes (PROs) in patients with active psoriatic arthritis (PsA). The researchers analyzed data from two phase 3 clinical trials, PSUMMIT 1 and PSUMMIT 2, to assess the impact of ustekinumab on physical function, health-related quality of life, and other patient-reported outcomes.

The study revealed that ustekinumab significantly improved PROs in patients with PsA, including those with prior treatment with methotrexate (MTX) or anti-tumor necrosis factor (TNF) agents. These improvements were observed across various measures, including physical function, pain, disease activity, and quality of life. Imagine a camel caravan facing a long and arduous journey - finding a source of relief and refreshment along the way can significantly improve their well-being. Similarly, ustekinumab offers relief and improvement for patients with PsA.

A Path to Relief for Psoriatic Arthritis

The study highlights the potential of ustekinumab as a valuable treatment option for patients with PsA, even those who have previously been treated with other medications. It underscores the importance of considering a variety of treatment approaches to address the complex needs of patients with this condition. Just like a camel caravan navigates a diverse desert landscape, we need to find the right resources and strategies to manage PsA effectively.

Dr.Camel's Conclusion

Ustekinumab offers significant benefits for patients with Psoriatic Arthritis, improving physical function, quality of life, and overall well-being. This study highlights the importance of individualized treatment approaches for this complex condition. Just like a camel caravan needs to adapt its strategy to navigate a diverse desert, we need to find the right combination of therapies to address the specific needs of each patient.

Date :
  1. Date Completed 2017-07-03
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

27483458

DOI: Digital Object Identifier

PMC5132036

Related Literature

Article Analysis
・Effective treatment of psoriatic arthritis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.